The companies that survive the current regulatory wave will be the kinds that moved in to the controlled market before the gray market collapsed. Accredited compounding pharmacies. Telehealth platforms with serious physician oversight. Manufacturers pursuing appropriate FDA pathways.Moving from direct client income to clinic distribution won't rout